Esperion Therapeutics Inc. (NASDAQ:ESPR) was down 0.4% during trading on Monday . The stock traded as low as $11.02 and last traded at $11.15, with a volume of 390,094 shares. The stock had previously closed at $11.19.

Several equities research analysts have recently commented on ESPR shares. Lake Street Capital lowered their price target on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, June 29th. Zacks Investment Research cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, April 6th. WallachBeth Capital cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 price objective for the company. in a report on Tuesday, July 5th. JMP Securities restated a “buy” rating and set a $67.00 price objective on shares of Esperion Therapeutics in a report on Thursday, June 16th. Finally, Credit Suisse Group AG cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $23.00 to $10.00 in a report on Wednesday, June 29th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $26.29.

The firm’s market cap is $249.88 million. The company has a 50 day moving average price of $15.19 and a 200 day moving average price of $16.26.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.09. On average, equities research analysts forecast that Esperion Therapeutics Inc. will post ($3.57) EPS for the current year.

In other news, CEO Timothy M. Mayleben acquired 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 4th. The stock was bought at an average price of $14.85 per share, with a total value of $103,950.00. Following the acquisition, the chief executive officer now owns 41,614 shares in the company, valued at approximately $617,967.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark E. Mcgovern acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The stock was purchased at an average cost of $10.00 per share, with a total value of $50,000.00. Following the acquisition, the director now owns 600 shares in the company, valued at approximately $6,000. The disclosure for this purchase can be found here.

An institutional investor recently bought a new position in Esperion Therapeutics stock. Oxford Asset Management acquired a new stake in Esperion Therapeutics Inc. (NASDAQ:ESPR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 155,077 shares of the biopharmaceutical company’s stock, valued at approximately $3,530,000. Oxford Asset Management owned approximately 0.69% of Esperion Therapeutics at the end of the most recent reporting period.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.